Sign Out
JADENU is contraindicated in patients with estimated creatinine clearance (ClCr) <60 mL/min or serum creatinine >2 times the age-appropriate upper limit of normal (ULN).
JADENU is contraindicated in high risk myelodysplastic syndrome (MDS) patients, any other MDS patient with a life expectancy < 1 year and patients with other hematological and non-hematological malignancies who are not expected to benefit from chelation therapy due to the rapid progression of their disease.
JADENU is contraindicated in patients with platelet counts < 50 x 109/L.
The use of JADENU (deferasirox) is contraindicated in patients with hypersensitivity to the active substance, deferasirox, or to any of the excipients. For a complete listing of excipients, see Description.
